Erythromycin Ethylsuccinate Shortage: What Providers and Prescribers Need to Know in 2026

This briefing is intended for clinicians prescribing Erythromycin Ethylsuccinate in the outpatient setting. It covers current supply status, clinical implications for specific indications, prescribing strategies to reduce fill failures, and tools available to help your patients access this medication.

Current Supply Status (2026)

Oral Erythromycin Ethylsuccinate (E.E.S. tablets and suspension) is

not on the FDA's current Drug Shortage List as of 2026. Active manufacturers include Amneal Pharmaceuticals NY LLC and Carnegie Pharmaceuticals LLC, with at least nine API suppliers globally per current DMF records.

However, real-world pharmacy availability is inconsistent. Key issues driving patient fill failures:

Reduced routine stocking at chain pharmacies due to declining Rx volume over the past 20 years

Suspension formulations particularly affected due to reconstitution requirements, refrigeration logistics, and limited shelf life after preparation

Seasonal demand spikes (pertussis season, back-to-school respiratory illness season) temporarily deplete available stock

Note: Erythromycin Lactobionate injection (ASHP shortage since April 2025) is a separate issue affecting inpatient care — not a direct substitute concern for outpatient prescribers

Indications Where E.E.S. Is Still Commonly Prescribed in 2026

Despite the availability of newer macrolides, Erythromycin Ethylsuccinate retains a clinical role in several specific scenarios:

Rheumatic fever prophylaxis in penicillin/sulfa-allergic patients: Per AHA guidelines, oral erythromycin 400mg BID is recommended for long-term secondary prophylaxis in patients who cannot tolerate penicillin or sulfonamides. This is a long-duration indication that requires reliable refill access.

Pertussis (whooping cough) in neonates and infants: Azithromycin is first-line for pertussis per CDC guidelines, but erythromycin ethylsuccinate remains an alternative — particularly relevant for newborns where appropriate dosing of alternatives may differ.

Chlamydial infections during pregnancy: E.E.S. has historically been used as an alternative for chlamydia in pregnancy, though azithromycin 1g single dose is now generally preferred by current guidelines.

Cost-driven prescribing: E.E.S. is one of the most affordable macrolide options for uninsured or underinsured patients — generic suspension as low as $15–$50 for a course.

Clinical Alternatives by Indication

When E.E.S. is unavailable, the following evidence-based alternatives are supported by current guidelines:

Streptococcal pharyngitis (penicillin-allergic): Azithromycin 500mg day 1, then 250mg days 2–5; or clarithromycin 250mg BID x 10 days; or clindamycin 300mg TID x 10 days

Pertussis: Azithromycin is CDC first-line (preferred for all ages including neonates); clarithromycin or TMP-SMX as alternatives

Chlamydia (non-pregnant adults): Doxycycline 100mg BID x 7 days (CDC preferred); azithromycin 1g single dose (alternative)

Rheumatic fever prophylaxis (penicillin/sulfa-allergic): Erythromycin 400mg BID is the AHA recommendation — no direct guideline-endorsed substitute exists for this specific indication. Consider referral to infectious disease or cardiology if supply is problematic.

CYP3A4 Interaction Profile: A Key Prescribing Consideration

Erythromycin is both a substrate and a potent inhibitor of CYP3A4. This has significant implications for patients on polypharmacy regimens. Clinically relevant interactions to screen for before prescribing E.E.S. include:

Warfarin: enhanced anticoagulation — monitor INR closely

Statins (lovastatin, simvastatin, atorvastatin): elevated statin levels — risk of myopathy/rhabdomyolysis

Cyclosporine / Tacrolimus: elevated immunosuppressant levels — potential nephrotoxicity

Colchicine: potentially life-threatening toxicity — contraindicated in renal/hepatic impairment

QT-prolonging drugs: additive QT prolongation risk — avoid in patients with QTc >470ms (women) / >450ms (men)

In polypharmacy patients, azithromycin's cleaner interaction profile may make it the more pragmatic choice when E.E.S. is clinically appropriate but supply is uncertain.

38,766+ patients found their medications in stock

38K+

Find Erythromycin Ethylsuccinate In Stock Today →

Prescribing Strategies to Reduce Fill Failures

Prescribe generically. Write for "erythromycin ethylsuccinate" rather than brand names (E.E.S. or EryPed) to maximize pharmacy flexibility in sourcing.

Specify formulation flexibility when clinically appropriate. If patient can use either tablet or suspension, note this on the prescription so the pharmacy can dispense whichever they have.

Direct patients to independent pharmacies. Chain pharmacies are less likely to stock E.E.S. routinely. Coaching patients to try independent pharmacies or specialty compounding pharmacies can prevent unnecessary callbacks to your office.

Use medfinder for providers. medfinder's provider tool helps your staff quickly locate pharmacies with confirmed E.E.S. stock before sending the prescription — reducing fill failures and patient frustration.

medfinder for Providers

medfinder's provider-facing platform lets your practice verify real-time pharmacy stock before prescribing. This is especially useful for medications like Erythromycin Ethylsuccinate that have variable availability. Visit medfinder.com/providers to learn how to integrate it into your workflow.

See also: How to help your patients find Erythromycin Ethylsuccinate in stock — a provider's guide.